Every medication article on this site is built on one document: the prescribing information, the label the FDA approved and the package insert that comes with the pen. The glossary at GLP-1 Words Decoded: A Plain-English Glossary defines the words. This page teaches the document itself, section by section, so a reader can find an answer in the source instead of searching for a stranger's summary of it. The numbering is the trick. Labels follow a fixed section scheme across almost all prescription drugs, which means once you can navigate one, you can navigate any of them.
The map: what lives where
Before section 1 comes the boxed warning, when there is one, set at the very top in its own border. The GLP-1 class carries one about thyroid C-cell tumors, and The Boxed Warning on Your GLP-1 Label, Explained reads it in full. Also near the start sits the revision history, a dry-looking list of dates and section numbers that turns out to be one of the most useful parts of the whole document, which we come back to at the end.
Then the numbered body. Section 1, Indications and Usage, states the approved uses in the populations studied, and it is the section people most often assume says more than it does; What GLP-1s Are Actually Approved to Treat consolidates it across the class. Section 2, Dosage and Administration, holds the starting dose, the escalation steps, the maintenance doses, what to do about missed doses, how and where to inject, and timing rules; several pages on this site live entirely inside it, including GLP-1 Titration Schedules Explained, Medication by Medication, Do I Have to Keep Increasing My Dose? and Does the Time of Day You Inject Matter?. Section 4, Contraindications, is the short, absolute list of who must not take the medicine at all. Section 5, Warnings and Precautions, is the numbered subsections where most of this site's side-effect articles begin. Section 6, Adverse Reactions, is the percentages.
The back half: section 7, Drug Interactions; section 8, Use in Specific Populations; sections 11 and 12, Description and Clinical Pharmacology, where the molecule, its mechanism and its half-life live; section 14, Clinical Studies, the trial tables; and section 17, Patient Counseling Information, the closest the label comes to being written for a patient.
Reading the percentages: always both columns
Section 6 deserves its own lesson, because it is where readers go wrong most reliably. The adverse reaction tables give each percentage twice, once for the medicine and once for placebo, and each number means nothing alone. A nausea figure of some percent on the drug reads very differently if the placebo column shows almost none of it than if the placebo column is close behind. Reading the medicine column without the placebo column is the classic mistake, and it manufactures both false alarm and false comfort, depending on which half you skip.
The same discipline carries into section 14. The clinical studies tables answer precise questions: which population, which dose, which duration, what was measured and against what comparator. A percentage in those tables is a description of a specific trial's participants under specific conditions. It is not a forecast for a reader, and the tables never claim to be one.
Section 8: the populations map
Section 8 is numbered in a fixed order, and knowing the order is what lets you jump straight to a question. Subsection 8.1 is pregnancy, 8.2 is lactation, 8.3 is females and males of reproductive potential, 8.4 is pediatric use, and 8.5 is geriatric use. Each of those subsections has a companion page on this site: GLP-1s and Pregnancy Planning: What the Labels Say, GLP-1s and Breastfeeding: What the Labels Say, GLP-1s and Adolescents: What the Labels Allow for 8.4, and GLP-1s After 65: What Changes for 8.5.
What the subsections say follows a pattern worth recognizing. Some state that use is established in a population, backed by trials, with ages and conditions named. Others state that safety and efficacy have not been established, which is a record of what was studied rather than a verdict. A reader who knows that 8.4 exists, and knows it varies by brand, can answer in one jump the question that takes most people an afternoon of contradictory forum posts.
The back of the label: pharmacology and the trial tables
Section 11, Description, says what the medicine physically is. Section 12, Clinical Pharmacology, says how it works and how the body handles it, and it is where the half-life figures live; the plain-English version for semaglutide is Semaglutide Half-Life: Understanding Your Medication Level. Section 14, Clinical Studies, is where the numbers actually come from: the tables of outcomes, side effect rates and laboratory measures that articles, including ones on this site, quote. When any page cites a percentage from a trial, this is the section it came from, and the reader who knows that can check the source directly.
GLP 1 Tracker AppYour doses, dates and notes, kept privately on your phone, so the label and the record sit side by side when a question comes up.
Get the app
Four habits that transfer to any label
Read the placebo column, always, in every table that has one. Treat an absence as what it is: a statement about evidence, not about safety. This site has made that point about kidney stones, fractures and NAION, where a label saying something was not studied is routinely read as a denial that anything could happen, or as proof of a cover-up, when it is neither. Watch for the population: an indication names a specific group, and the trial behind it enrolled a narrower one still, which is why a label can be exactly right and still not be about you. And mind the dates.
The dates deserve the last word, because labels change. The revision history at the front lists which sections changed and when, and it is how anyone can see that a warning was added or removed. It happened recently: in February 2026 the suicidal behavior and ideation section was removed from three GLP-1 labels, a change covered at GLP-1s and Mood: What the Regulators Concluded. A printout from a year ago may not match the current label, which is why the current version is the one worth consulting: it lives in the FDA's own labeling database, and any pharmacist can print it.
Frequently asked questions
Where do I find the official prescribing information for my GLP-1?
In the FDA's own labeling database, which lists the current version of every approved label, or from a pharmacist, who can print the package insert that accompanies the medication. The copy that comes in the box is the same document. Because labels are revised, the version to consult is the current one rather than a printout that has sat in a drawer since the prescription was first filled.
What is section 8.4 of a drug label?
Section 8.4 is Pediatric Use, one subsection of section 8, Use in Specific Populations. It states whether the medicine's safety and efficacy have been established in children, and in which ages and conditions. Its neighbors are 8.1 Pregnancy, 8.2 Lactation, 8.3 Females and Males of Reproductive Potential and 8.5 Geriatric Use. For GLP-1s, 8.4 is where the pediatric age floors live, and it varies by brand even for the same molecule.
Why do side effect percentages in the label appear in two columns?
Because section 6, Adverse Reactions, reports each percentage for the medicine and for placebo side by side. Nausea at some rate on the drug means one thing if placebo was near zero and another if placebo was close behind. Reading the medicine column without the placebo column is the classic mistake in interpreting these tables, and the two together are the only honest way to read them.
What does it mean when a label says something was not studied?
It is a statement about evidence, not about safety. A section saying a medicine has not been studied in a population, or that data are limited, records what the trials examined, and nothing about what would happen if it were used. Absence of a finding is not a finding of absence of risk, and it is also not proof of a hidden problem. It simply marks the edge of what is known.
How can I tell if my GLP-1 label is out of date?
Check the revision history, usually printed at the start of the label, which lists each change by section and date. Labels change without the box changing: a warning can be added or removed, and in February 2026 the suicidal behavior and ideation section was removed from three GLP-1 labels. Comparing your printout's revision date against the current version in the FDA's labeling database settles the question in a minute.